Insider Selling: Cerus Co. (NASDAQ:CERS) CEO Sells $35,685.65 in Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 23,023 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $1.55, for a total transaction of $35,685.65. Following the sale, the chief executive officer now directly owns 3,230,000 shares of the company’s stock, valued at $5,006,500. This represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Cerus Price Performance

CERS stock opened at $1.51 on Friday. The firm has a market capitalization of $280.54 million, a PE ratio of -13.73 and a beta of 1.56. Cerus Co. has a one year low of $1.38 and a one year high of $2.54. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. The firm has a 50-day moving average of $1.74 and a two-hundred day moving average of $1.80.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. On average, analysts forecast that Cerus Co. will post -0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Hedge Funds Weigh In On Cerus

Large investors have recently made changes to their positions in the business. Rockport Wealth LLC acquired a new position in shares of Cerus in the 4th quarter valued at about $25,000. Cibc World Markets Corp acquired a new position in Cerus in the fourth quarter worth approximately $26,000. R Squared Ltd bought a new stake in Cerus during the fourth quarter worth approximately $29,000. Virtu Financial LLC bought a new stake in Cerus during the fourth quarter worth approximately $33,000. Finally, Dark Forest Capital Management LP bought a new stake in Cerus during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.